Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
123I-labeled anti-CEA Fab
- Development stage
- Unknown
- Lead developer
- University of Lausanne
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
123I-labeled anti-CEA Fab is a diagnostic radiopharmaceutical consisting of the Fab fragment of a monoclonal antibody specific for carcinoembryonic antigen (CEA), radiolabeled with the gamma-emitting isotope Iodine-123. Developed for the localization of primary, recurrent, and metastatic colorectal carcinoma, it is used in conjunction with emission-computerized tomography (ECT). The use of the Fab fragment, which lacks the Fc portion of the antibody, allows for significantly faster blood clearance and reduced non-specific background signaling compared to intact IgG or F(ab')2 fragments. This pharmacokinetic profile enables high-contrast tumor imaging as early as 6 to 24 hours post-injection, facilitating the detection of small tumor masses and recurrences even in patients with normal circulating CEA levels.
- Other names
- 123I-labeled Fab123I-anti-CEA FabIodine-123 labeled Fab fragmentIodine123 labeled Fab fragmentIodine 123 labeled Fab fragment123I-labeled monoclonal antibody fragment
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)CEACAM6
Beyond the preview
Go deeper on 123I-labeled anti-CEA Fab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 123I-labeled anti-CEA Fab.